Form 4: vTv Therapeutics Director Acquires Stock Options

Srinivas Akkaraju, a director at vTv Therapeutics, acquired stock options on June 25, 2024, according to a recent SEC Form 4 filing.

Summary

• A Form 4 filing reveals that Srinivas Akkaraju, a director of vTv Therapeutics Inc. (VTVT), acquired stock options on June 25, 2024.
• Akkaraju acquired two sets of director stock options: 2,250 options and 983 options, both with an exercise price of $17.22.
• The 2,250 options vest monthly over three years from the grant date and expire on June 25, 2034.
• The 983 options vest fully on the one-year anniversary of the grant date and also expire on June 25, 2034.
• Following the transaction, Akkaraju directly owns 6,983 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, such as directors and officers. This filing indicates routine compensation in the form of stock options.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates

Keywords

Form 4, stock options, director, VTVT, vTv Therapeutics, Srinivas Akkaraju, beneficial ownership